| 000 | 03138nam a22004695i 4500 | ||
|---|---|---|---|
| 001 | vtls000541805 | ||
| 003 | RU-ToGU | ||
| 005 | 20210922082311.0 | ||
| 007 | cr nn 008mamaa | ||
| 008 | 160915s2014 sz | s |||| 0|eng d | ||
| 020 |
_a9783034807098 _9978-3-0348-0709-8 |
||
| 024 | 7 |
_a10.1007/978-3-0348-0709-8 _2doi |
|
| 035 | _ato000541805 | ||
| 040 |
_aSpringer _cSpringer _dRU-ToGU |
||
| 050 | 4 | _aRM1-950 | |
| 072 | 7 |
_aMMG _2bicssc |
|
| 072 | 7 |
_aMED071000 _2bisacsh |
|
| 082 | 0 | 4 |
_a615 _223 |
| 245 | 1 | 0 |
_aIndacaterol _helectronic resource _bThe First Once-daily Long-acting Beta2 Agonist for COPD / _cedited by Alexandre Trifilieff. |
| 260 |
_aBasel : _bSpringer Basel : _bImprint: Springer, _c2014. |
||
| 300 |
_aVII, 146 p. 41 illus., 21 illus. in color. _bonline resource. |
||
| 336 |
_atext _btxt _2rdacontent |
||
| 337 |
_acomputer _bc _2rdamedia |
||
| 338 |
_aonline resource _bcr _2rdacarrier |
||
| 490 | 1 |
_aMilestones in Drug Therapy, _x2296-6056 |
|
| 505 | 0 | _aCurrent Pharmacotherapy for COPD -- The preclinical pharmacology of indacaterol -- The design of the indacaterol molecule -- The early clinical development of Indacaterol -- INHANCE: An adaptive confirmatory study with dose selection at interim -- Phase III clinical efficacy studies – lung function -- Phase III Clinical Efficacy of Indacaterol -- Patient-centered Outcomes -- The history and performance of the Breezhaler device -- What does the future hold for the therapy of COPD? . | |
| 520 | _aChronic obstructive pulmonary disease (COPD) is a multi-component condition that results in increasingly limited airflow, usually associated with an abnormal inflammatory response of the lung. It constitutes a major public health burden worldwide, while only very few effective therapies are available. This book provides a comprehensive overview of the development of Onbrez Breezhaler, a newly approved once-daily inhaled β2 agonist for the treatment of COPD. It reviews the current pharmacotherapy for COPD and discusses topics such as the chemical design and the pre-clinical pharmacology of the molecule, the early clinical development, the INHANCE study (which provides a successful example of the use of an adaptive design in the confirmatory setting) and the Phase III clinical efficacy study, as well as the history and performance of the Breezhaler device. Finally, a list of emerging targets is included that could well offer future treatment options for COPD. | ||
| 650 | 0 |
_amedicine. _9566220 |
|
| 650 | 0 |
_aToxicology. _9302218 |
|
| 650 | 0 |
_aPneumology. _9304224 |
|
| 650 | 1 | 4 |
_aBiomedicine. _9566246 |
| 650 | 2 | 4 |
_aPharmacology/Toxicology. _9302222 |
| 650 | 2 | 4 |
_aPneumology/Respiratory System. _9304226 |
| 700 | 1 |
_aTrifilieff, Alexandre. _eeditor. _9448030 |
|
| 710 | 2 |
_aSpringerLink (Online service) _9143950 |
|
| 773 | 0 | _tSpringer eBooks | |
| 830 | 0 |
_aMilestones in Drug Therapy, _9330476 |
|
| 856 | 4 | 0 | _uhttp://dx.doi.org/10.1007/978-3-0348-0709-8 |
| 912 | _aZDB-2-SBL | ||
| 999 | _c399933 | ||